Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study DOI Creative Commons

Qingdan Liu,

MeiLan K. Han, Meilan Li

et al.

Lipids in Health and Disease, Journal Year: 2023, Volume and Issue: 22(1)

Published: Oct. 28, 2023

Abstract Background Variations in the prevalence and systemic inflammatory (SI) status between non-alcoholic fatty liver disease (NAFLD) newly defined metabolic dysfunction-associated (MAFLD) have only been reported by few studies. Hence, this study aimed to compile data on inflammation levels of MAFLD NAFLD a general population from Southeast China was summarized explore potential effect transformation definition. Methods A total 6718 participants aged 35–75 were enrolled. Logistic regression restricted cubic spline (RCS) models used examine relationship 15 SI indicators MAFLD. The predicted values analyzed using receiver operating characteristic (ROC) curve. Results 34.7% 32.4%, respectively. Their overlapping rate 89.7%, while 8.3% 1.9% MAFLD-only NAFLD-only. Among three FLD groups, group had highest 8 indicators, including CRP, WBC, LYMPH, NEUT, MONO, ALB, NLR, SIRI. non-FLD lower all compared with subgroups. odds ratios (ORs) 10 significant both multivariable-adjusted logistic RCS analyses or NAFLD, PLR, LMR, ALI CA. ROC analysis showed that AUC than 0.7 NAFLD. Conclusions could cover more severe status, whereas NAFLD-only exhibited levels. Moreover, there not high sensitivity suggesting are good diagnose NAFLD/MAFLD.

Language: Английский

MAFLD: How is it different from NAFLD? DOI Creative Commons
Cameron Gofton,

Yadhavan Upendran,

Ming‐Hua Zheng

et al.

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S17 - S31

Published: Nov. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Language: Английский

Citations

245
Global multi-stakeholder endorsement of the MAFLD definition DOI
Nahúm Méndez‐Sánchez, Elisabetta Bugianesi, Robert G. Gish

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2022, Volume and Issue: 7(5), P. 388 - 390

Published: March 3, 2022

Language: Английский

Citations

209
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight DOI
Mohammed Eslam, Hashem B. El–Serag, Sven Francque

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2022, Volume and Issue: 19(10), P. 638 - 651

Published: June 16, 2022

Language: Английский

Citations

165
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity DOI Creative Commons
Gi‐Ae Kim, Joon Ho Moon, Won Kim

et al.

Clinical and Molecular Hepatology, Journal Year: 2023, Volume and Issue: 29(4), P. 831 - 843

Published: Aug. 27, 2023

The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word 'fatty.' Three pan-national associations set out explore a new nomenclature replace both NAFLD suggested alternative, metabolic (dysfunction)-associated (MAFLD). They surveyed if change in and/or definition is favored which best communicates characteristics increases awareness. In lieu NAFLD/MAFLD, dysfunction-associated steatotic (MASLD) been chosen, an umbrella term, (SLD), encompassing whole spectrum disease, proposed. It that cardiometabolic risk factors should be considered when categorizing SLD patients. Furthermore, subcategory, MASLD with increased alcohol intake (MetALD), casts light on neglected group patients moderate or more consumption. importance dysfunction was acknowledged this nomenclature, but precise contribution consumption development progression remains unclear. Herein, we review hepatologists' endocrinologists' perspectives along possible impact clinical practice. Although it premature predict settlement may help build evidence for soft landing future.

Language: Английский

Citations

72
Natural history of metabolic dysfunction-associated steatotic liver disease DOI
Vasileios Lekakis, George Papatheodoridis

European Journal of Internal Medicine, Journal Year: 2023, Volume and Issue: 122, P. 3 - 10

Published: Nov. 7, 2023

Language: Английский

Citations

58
The Rotterdam Study. Design update and major findings between 2020 and 2024 DOI
M. Arfan Ikram, Brenda C.T. Kieboom, Willem Pieter Brouwer

et al.

European Journal of Epidemiology, Journal Year: 2024, Volume and Issue: 39(2), P. 183 - 206

Published: Feb. 1, 2024

Language: Английский

Citations

34
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies DOI Creative Commons
Mohammad Habibullah,

Khaleed Jemmieh,

Amr Ouda

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Jan. 23, 2024

Background Metabolic associated fatty liver disease (MAFLD) is a novel terminology introduced in 2020 to provide more accurate description of with metabolic dysfunction. It replaces the outdated term nonalcoholic (NAFLD) and aims improve diagnostic criteria tailored treatment strategies for disease. NAFLD, most prevalent western industrialized nations, has been steadily increasing prevalence serious complications such as cirrhosis hepatocellular carcinoma. also linked insulin resistance syndrome cardiovascular diseases. However, current studies on NAFLD have limitations meeting necessary histological endpoints. Objective This literature review consolidate recent knowledge discoveries concerning MAFLD, integrating diverse aspects Specifically, it focuses analyzing differentiating from alcoholic (AFLD), exploring epidemiology, clinical manifestations, pathogenesis, management approaches MAFLD. The explores associations between MAFLD other conditions. discusses heightened mortality risk its link chronic kidney (CKD), showing that exhibits enhanced accuracy identifying patients CKD compared NAFLD. association incident/prevalent supported by cohort meta-analyses. Conclusion highlights importance distinct provides insights into criteria, CKD, Further research needed develop tools advanced fibrosis explore underlying mechanisms linking serves valuable resource researchers healthcare professionals seeking comprehensive understanding

Language: Английский

Citations

31
MAFLD identifies patients with significant hepatic fibrosis better than MASLD DOI
Ziyan Pan, Said A. Al‐Busafi, Maheeba Abdulla

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(3), P. 964 - 972

Published: May 8, 2024

Language: Английский

Citations

19
Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study DOI Creative Commons
Ibrahim Ayada, Laurens A. van Kleef, Huai Zhang

et al.

EBioMedicine, Journal Year: 2022, Volume and Issue: 87, P. 104392 - 104392

Published: Dec. 8, 2022

Language: Английский

Citations

63
MAFLD: an optimal framework for understanding liver cancer phenotypes DOI Creative Commons
Harry Crane, Cameron Gofton, Ankur Sharma

et al.

Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 58(10), P. 947 - 964

Published: July 20, 2023

Hepatocellular carcinoma has a substantial global mortality burden which is rising despite advancements in tackling the traditional viral risk factors. Metabolic (dysfunction) associated fatty liver disease (MAFLD) most prevalent disease, increasing parallel with epidemics of obesity, diabetes and systemic metabolic dysregulation. MAFLD major factor behind this sustained rise HCC incidence, both as single entity often via synergistic interactions other diseases. Mechanisms MAFLD-related are complex but crucially underpinned by dysregulation variable contributions from interacting modifiers related to environment, genetics, dysbiosis immune distinct clinical presentation, notably its common occurrence non-cirrhotic disease. This just one several challenges effective surveillance programmes. The response immune-checkpoint therapy currently controversial, further complicated high prevalence individuals aetiologies. In review, we highlight current data on epidemiology, characteristics, outcomes screening controversies. addition, concepts that have arisen because paradigm such MAFLD/NAFLD non-overlapping groups, dual aetiology tumours sub-phenotypes reviewed.

Language: Английский

Citations

27